CLINICAL TRIALS PROFILE FOR SAFFLOWER OIL; SOYBEAN OIL
✉ Email this page to a colleague
All Clinical Trials for safflower oil; soybean oil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00396461 ↗ | ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients | Terminated | B. Braun Medical SA | Phase 4 | 2006-11-01 | This study aims to analyse the effect of two total parenteral nutrition diets with lipid emulsions of different compositions on the incidence of nosocomial infection in critical patients. One diet will contain an MCT/LCT emulsion concentrated to 20% (50:50 ratio) and the other will comprise an MCT/LCT/fish oil emulsion (50:40:10 ratio). The secondary objective of this study is to analyse mortality in hospital and up to 6 months of discharge. |
| NCT01373918 ↗ | Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders | Terminated | St. Louis University | Phase 4 | 2010-12-01 | Neonates with congenital/acquired gastrointestinal disorders are at high risk for Parenteral Nutrition Associated Cholestasis (PNAC). Besides enteral nutrition, standard therapies to prevent and treat PNAC have been limited and marginal. Recently, the dose and composition of standard intravenous fat emulsions have implicated in the development and progression of PNAC. In this study, neonates with congenital/acquired gastrointestinal disorders will be randomized, in a unblinded fashion, to receive either the standard dose of an intravenous omega-6 fatty acid emulsion or a low dose of an intravenous omega-6 fatty acid emulsion throughout their course of PN or until hospital discharge, death or 100 days of life, whichever comes first. The primary outcome will be the presence of cholestasis. |
| NCT01373918 ↗ | Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders | Terminated | University of California, Los Angeles | Phase 4 | 2010-12-01 | Neonates with congenital/acquired gastrointestinal disorders are at high risk for Parenteral Nutrition Associated Cholestasis (PNAC). Besides enteral nutrition, standard therapies to prevent and treat PNAC have been limited and marginal. Recently, the dose and composition of standard intravenous fat emulsions have implicated in the development and progression of PNAC. In this study, neonates with congenital/acquired gastrointestinal disorders will be randomized, in a unblinded fashion, to receive either the standard dose of an intravenous omega-6 fatty acid emulsion or a low dose of an intravenous omega-6 fatty acid emulsion throughout their course of PN or until hospital discharge, death or 100 days of life, whichever comes first. The primary outcome will be the presence of cholestasis. |
| NCT01845116 ↗ | Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury | Completed | Atrium Health | Phase 2 | 2010-07-01 | The purpose of this study is to determine whether the omega-3 fatty acid emulsion (Omegaven®), when used in place of the conventional soy-based fat emulsion (Intralipid), is effective in treating parenteral nutrition associated liver disease (PNALD) in children. The study hypothesis is that Omegaven® can be safely provided to children who are dependent on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD until the child can take adequate nutrition by mouth. |
| NCT01845116 ↗ | Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury | Completed | Carolinas Healthcare System | Phase 2 | 2010-07-01 | The purpose of this study is to determine whether the omega-3 fatty acid emulsion (Omegaven®), when used in place of the conventional soy-based fat emulsion (Intralipid), is effective in treating parenteral nutrition associated liver disease (PNALD) in children. The study hypothesis is that Omegaven® can be safely provided to children who are dependent on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD until the child can take adequate nutrition by mouth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for safflower oil; soybean oil
Condition Name
Clinical Trial Locations for safflower oil; soybean oil
Trials by Country
Clinical Trial Progress for safflower oil; soybean oil
Clinical Trial Phase
Clinical Trial Sponsors for safflower oil; soybean oil
Sponsor Name
